Triple-negative breast cancer: unmet needs and emerging targeted and immunotherapeutic approaches
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20262883Keywords:
Triple-negative breast cancer, Antibody drug conjugates, Molecular targets, Tumor heterogeneity, Drug resistance, Liquid biopsyAbstract
Triple-negative breast cancer (TNBC) is a tough type of breast cancer. It does not have estrogen, progesterone, or HER2 receptors. This makes it hard to treat because common hormone and HER2 therapies do not work, often leading to poor results. To look at new treatments for TNBC, focusing on new molecular targets, antibody-drug conjugates (ADCs), immunotherapy, resistance issues, and future personalized medicine. A detailed review was done, combining information from molecular biology, clinical trials, immuno-oncology, and new technologies like artificial intelligence and liquid biopsy to assess progress in TNBC treatment. TNBC is very diverse at the molecular level, involving pathways like PI3K/AKT, TP53 mutations, and DNA repair problems. New treatments include ADCs like sacituzumab govitecan targeting TROP-2, and immune checkpoint inhibitors targeting PD-1/PD-L1 pathways, which have helped some patients live longer. Combining ADCs and immunotherapy shows better results by causing cancer cells to die in a way that triggers the immune system. However, resistance to treatment is still a big problem due to tumor diversity, loss of antigens, poor drug delivery, and resistance to the drug's effects. Advances in liquid biopsy, ctDNA monitoring, and AI-driven models are helping create real-time, personalized treatment plans. TNBC treatment is moving from standard chemotherapy to more precise approaches using targeted therapies, immunotherapy, and flexible treatment plans. Despite progress, overcoming resistance and improving long-term survival need more research into biomarkers, combination therapies, and personalized medicine.
References
Peters RE, al-Ismail S. Immunophenotyping of normal lymphocytes. Clin Lab Haematol 1994;16(1):21-32.
Schmid P, Dent R, O’Shaughnessy J. Pembrolizumab for early triple-negative breast cancer. Reply. N Engl J Med. 2020;382(26):e108.
Gouda MA, Subbiah V. Tissue-agnostic cancer therapy approvals. Surg Oncol Clin N Am. 2024;33(2):243-64.
Telisnor G, DeRemer DL, Frimpong E, Agyare E, Allen J, Ricks-Santi L, et al. Review of genetic and pharmacogenetic differences in cytotoxic and targeted therapies for pancreatic cancer in African Americans. J Natl Med Assoc .2023;115(2):164-74.
Xian P, Zou L, Zhang J, Pan X, Song Y, Nan Y, et al. Precision targeted cancer-associated fibroblast nano-regulator enhanced chemo-immunotherapy for triple-negative breast cancer. Biomaterials. 2026;326:123679.
Cetin B, Gumusay O. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(26):e108.
Lehmann BD, Abramson VG, Dees EC, Shah PD, Ballinger TJ, Isaacs C, et al. Atezolizumab in combination with carboplatin and survival outcomes in patients with metastatic triple-negative breast cancer: The TBCRC 043 phase 2 randomized clinical trial: The TBCRC 043 phase 2 randomized clinical trial. JAMA Oncol. 2024;10(2):193-201.
FDA. Highlights of Prescribing Information. Available at: https://www.accessdata.fda.gov/ drugsatfda_docs/label/2022/761034s043lbl.pdf. Accessed on 15 May 2026.
Gorenšek R, Kresnik M, Takač I, Rojko T, Sobočan M. Advances in tumour-infiltrating lymphocytes for triple-negative breast cancer management. Breast Cancer (Dove Med Press). 2023;15:773-83.
Doherty MR, Jackson MW. The critical, clinical role of interferon-beta in regulating cancer stem cell properties in triple-negative breast cancer. DNA Cell Biol. 2018;37(6):513-6.
Zheng C, Xu X, Wu M, Xue L, Zhu J, Xia H, et al. Neutrophils in triple-negative breast cancer: an underestimated player with increasingly recognized importance. Breast Cancer Res. 2023;25(1):88.
Yadav BS, Chanana P, Jhamb S. Biomarkers in triple negative breast cancer: A review. World J Clin Oncol. 2015;6(6):252-63.
Kelloff GJ, Sigman CC. Cancer biomarkers: selecting the right drug for the right patient. Nat Rev Drug Discov. 2012;11(3):201-14.
Matar-Ujvary R, Fecanji K, Sevilimedu V, Montagna G, Gemignani ML. Impact of age on outcomes in women with triple-negative breast cancer treated with neoadjuvant chemotherapy. J Adolesc Young Adult Oncol. 2026:21565333261421530.
Yuan Z, Liu Z, Zhou M, Wen H, Li B. Research progress on immunotherapeutics for triple-negative breast cancer from a single-cell perspective. Crit Rev Oncol Hematol. 2026;218:105111.
Jabbarzadeh Kaboli P, Shabani S, Sharma S, Partovi Nasr M, Yamaguchi H, Hung M-C. Shedding light on triple-negative breast cancer with Trop2-targeted antibody-drug conjugates. Am J Cancer Res. 2022;12(4):1671-85.
Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014;2(4):361-70.
Fan Y, He S. The characteristics of tumor microenvironment in triple negative breast cancer. Cancer Manag Res. 2022;14:1-17.
Lee KJ, Mann E, Wright G, Piett CG, Nagel ZD, Gassman NR. Exploiting DNA repair defects in triple negative breast cancer to improve cell killing. Ther Adv Med Oncol. 2020;12:1758835920958354.
Ossovskaya V, Wang Y, Budoff A, Xu Q, Lituev A, Potapova O, et al. Exploring molecular pathways of triple-negative breast cancer. Genes Cancer. 2011;2(9):870-9.
Nagayama A, Vidula N, Ellisen L, Bardia A. Novel antibody-drug conjugates for triple negative breast cancer. Ther Adv Med Oncol. 2020;12:1758835920915980.
Jiang K, Wang S. Advances in antibody-drug conjugates in the treatment of advanced triple-negative breast cancer: a narrative review. Transl Breast Cancer Res. 2025;6(0):9.
Beck A, Goetsch L, Dumontet C, Corvaïa N. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315-37.
Peters C, Brown S. Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep. 2015;35(4):e00225.
Pettinato MC. Introduction to antibody-drug conjugates. Antibodies (Basel). 2021;10(4):42.
Diamantis N, Banerji U. Antibody-drug conjugates--an emerging class of cancer treatment. Br J Cancer. 2016;114(4):362-7.
Kang C. Sacituzumab govitecan: A review in unresectable or metastatic HR+/HER2- breast cancer. Target Oncol. 2024;19(2):289-96.
López de Sá A, Díaz-Tejeiro C, Poyatos-Racionero E, Nieto-Jiménez C, Paniagua-Herranz L, Sanvicente A, et al. Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned. J Hematol Oncol. 2023;16(1):118.
Rosa K. Sacituzumab govitecan prompts clinical benefit in metastatic TNBC, regardless of Trop-2 expression. CancerNetwork. 2020. Available at: https://www.cancernetwork.com/view/sacituzumab-govitecan-prompts-clinical-benefit-in-metastatic-tnbc-regardless-of-trop-2-expression. Accessed on 15 May 2026.
Clinical Review. Canadian Agency for Drugs and Technologies in Health. 2022. Available at: https://www.cda-amc.ca/. Accessed on 15 May 2026.
Pérez-Bermejo M, Caballero-Pascual M, Legidos-García ME, Martínez-Peris M, Casaña-Mohedo J, Llorca-Colomer F, et al. Sacituzumab Govitecan in Triple Negative Breast Cancer: A Systematic Review of Clinical Trials. Cancers (Basel). 2024;16(21):3622.
Peters RE, al-Ismail S. Immunophenotyping of normal lymphocytes. Clin Lab Haematol. 1994;16(1):21-32.
Schmid P, Dent R, O’Shaughnessy J. Pembrolizumab for early triple-negative breast cancer. Reply. N Engl J Med. 2020;382(26):e108.
Gouda MA, Subbiah V. Tissue-agnostic cancer therapy approvals. Surg Oncol Clin N Am. 2024;33(2):243-64.
Telisnor G, DeRemer DL, Frimpong E, Agyare E, Allen J, Ricks-Santi L, et al. Review of genetic and pharmacogenetic differences in cytotoxic and targeted therapies for pancreatic cancer in African Americans. J Natl Med Assoc. 2023;115(2):164-74.
Xian P, Zou L, Zhang J, Pan X, Song Y, Nan Y, et al. Precision targeted cancer-associated fibroblast nano-regulator enhanced chemo-immunotherapy for triple-negative breast cancer. Biomaterials. 2026;326:123679.
Cetin B, Gumusay O. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(26):e108.
Lehmann BD, Abramson VG, Dees EC, Shah PD, Ballinger TJ, Isaacs C, et al. Atezolizumab in combination with carboplatin and survival outcomes in patients with metastatic triple-negative breast cancer: The TBCRC 043 phase 2 randomized clinical trial: The TBCRC 043 phase 2 randomized clinical trial. JAMA Oncol. 2024;10(2):193-201.
FDA. Highlights of Prescribing Information. Available at: https://www.accessdata.fda.gov/drugs atfda_docs/label/2022/761034s043lbl.pdf. Accessed on 15 May 2026
Gorenšek R, Kresnik M, Takač I, Rojko T, Sobočan M. Advances in tumour-infiltrating lymphocytes for triple-negative breast cancer management. Breast Cancer (Dove Med Press). 2023;15:773-83.
Doherty MR, Jackson MW. The critical, clinical role of interferon-beta in regulating cancer stem cell properties in triple-negative breast cancer. DNA Cell Biol]. 2018;37(6):513-6.
Zheng C, Xu X, Wu M, Xue L, Zhu J, Xia H, et al. Neutrophils in triple-negative breast cancer: an underestimated player with increasingly recognized importance. Breast Cancer Res. 2023;25(1):88.
Yadav BS, Chanana P, Jhamb S. Biomarkers in triple negative breast cancer: A review. World J Clin Oncol. 2015;6(6):252-63.
Kelloff GJ, Sigman CC. Cancer biomarkers: selecting the right drug for the right patient. Nat Rev Drug Discov. 2012;11(3):201-14.
Beck A, Goetsch L, Dumontet C, Corvaïa N. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315-37.
Catanzaro E, Beltrán-Visiedo M, Galluzzi L, Krysko DV. Immunogenicity of cell death and cancer immunotherapy with immune checkpoint inhibitors. Cell Mol Immunol. 2025;22(1):24-39.
Xu X, Yu T, Wang Z. Combining antibody-drug conjugates with immune checkpoint inhibitors: A new paradigm for breast cancer therapy. Cancer Treatment Rev. 2025;140:103012.
Dou L, Fang Y, Yang H, Ai G, Shen N. Immunogenic cell death: A new strategy to enhancing cancer immunotherapy. Hum Vaccin Immunother. 2024;20(1):2437918.
Liu Q, Hu Y, Zheng P, Yang Y, Fu Y, Yang Y, et al. Exploiting immunostimulatory mechanisms of immunogenic cell death to develop membrane-encapsulated nanoparticles as a potent tumor vaccine. J Nanobiotechnology. 2023;21(1):326.
Wikipedia: The Free Encyclopedia. Antineoplastic resistance. Available at: https://en.wikipedia.org/ w/index.php?title=Antineoplastic_resistance&oldid=1314027404. Accessed on 15 May 2026.
Zhou Z, Zhou Q. Immunotherapy resistance in triple-negative breast cancer: Molecular mechanisms, tumor microenvironment, and therapeutic implications. Front Oncol. 2025;15:1630464.
Abelman RO, Wu B, Spring LM, Ellisen LW, Bardia A. Mechanisms of Resistance to Antibody-Drug Conjugates. Cancers (Basel). 2023;15(4):1278.
Khoury R, Saleh K, Khalife N, Saleh M, Chahine C, Ibrahim R, et al. Mechanisms of Resistance to Antibody-Drug Conjugates. Int J Mol Sci. 2023;24(11):9674.
Rasche M, Steidel E, Zimmermann M, Bourquin JP, Boztug H, Janotova I, et al. Second Relapse of Pediatric Patients with Acute Myeloid Leukemia: A Report on Current Treatment Strategies and Outcome of the AML-BFM Study Group. Cancers (Basel). 2021;13(4):789.
Liang K, Mei S, Gao X, Peng S, Zhan J. Dynamics of Endocytosis and Degradation of Antibody-Drug Conjugate T-DM1 in HER2 Positive Cancer Cells. Drug Des Devel Ther. 2021;15:5135-50.
Li S, Zhao X, Fu K, Zhu S, Pan C, Yang C, et al. Resistance to antibody-drug conjugates: A review. Acta Pharm Sin B. 2025;15(2):737-56.
Downloads
Published
How to Cite
Issue
Section
